NASDAQ · Biotechnology · USD
Edesa Biotech, Inc. (EDSA) Stock Analysis
Edesa Biotech, Inc. (EDSA) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.
Last Updated: October 21, 2026
Price History
No price data available
Hover for the daily close. The dotted line marks the period open.
EDSA Key Statistics
As of Oct 21, 2026Trading
- Open
- $2.87
- Previous Close
- $2.82
- Day's Range
- 2.70–2.93
- 52-Week Range
- 0.72–20.32
- Volume
- 39.16K
- BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
- 1.22
Valuation
- Market Cap
- $38.51M
- P/E Ratio
- unprofitable
- EPS (ttm)Profit attributable to each share over the last twelve months.
- −1.72
Financials (FY)
- Revenue (FY)
- $0.00
- Net Income (FY)
- −$7.19M
- Shares Outstanding
- 13.51M
- 1-Year Return
- +5.17%
Dividend and dates
- Avg Volume
- 62.31K
Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.
Key facts
As of October 21, 2026, EDSA closed at $2.85, +5.17% over 1 year.
Edesa Biotech, Inc. (EDSA) has a market capitalization of $38.51M.
In fiscal 2025, EDSA reported revenue of $0.00.
EDSA Stock Return by Calendar Year
Edesa Biotech, Inc. (EDSA) 10-year return: what $10,000 became
- 1 year
- $10,000 $10,517
- +5.17%
- 5 years
- $10,000 $500
- −95.00%
- 10 years
- $10,000 $48
- −99.52%
If you had invested $10,000 in Edesa Biotech, Inc. (EDSA) 10 years ago, at the close on October 21, 2016, it would have been worth $48 at the close on October 21, 2026: −99.52% in total, −41.40% a year. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.
Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.
| Year | Return |
|---|---|
| 2026 (partial year) | +100.70% |
| 2025 | −15.48% |
| 2024 | −63.24% |
| 2023 | −69.78% |
| 2022 | −61.63% |
| 2021 | +32.47% |
| 2020 | +3.66% |
| 2019 | −24.91% |
| 2018 | −83.95% |
| 2017 | −60.10% |
| 2016 (partial year) | −30.95% |
As of October 21, 2026.
EDSA Revenue and Earnings by Fiscal Year
FY ends September| Fiscal year | Revenue | Net income | Net margin |
|---|---|---|---|
| 2025 | $0.00 | −$7.19M | — |
| 2024 | $0.00 | −$6.17M | — |
| 2023 | $0.00 | −$8.37M | — |
| 2022 | $0.00 | −$17.55M | — |
| Fiscal year | Revenue | Gross profit | Operating income | Net income | Net margin |
|---|---|---|---|---|---|
| 2025 | $0.00 | — | −$7.13M | −$7.19M | — |
| 2024 | $0.00 | — | −$6.32M | −$6.17M | — |
| 2023 | $0.00 | — | −$8.64M | −$8.37M | — |
| 2022 | $0.00 | — | −$17.59M | −$17.55M | — |
Annual figures as reported, in the company's reporting currency. As of September 30, 2025.
Recent News
Edesa Biotech Announces FDA IND Clearance for Phase 2 Vitiligo Study
YahooEdesa Biotech Receives FDA Clearance For Its Investigational New Drug Application For Its Phase 2 Clinical Trial Of EB06 In Vitiligo
BenzingaEdesa Biotech Stock Sinks After Fresh Capital Raise
BenzingaEdesa Biotech Commences Common Stock Offering; Terms Undisclosed
BenzingaEdesa Biotech Q3 EPS $(0.60) Misses $(0.58) Estimate
Benzinga
News provided by third-party sources. Not financial advice.
Analysis
Data-derivedEvery figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.
Related Biotechnology Stocks
Vertex Pharmaceuticals Incorporated
$132.95B
MRNAModerna, Inc.
$98.14B
REGNRegeneron Pharmaceuticals, Inc.
$82.95B
ARGXargenx SE
$55.97B
ONCBeOne Medicines AG
$43.97B
RVMDRevolution Medicines, Inc.
$41.64B
Popular Healthcare Stocks
Eli Lilly and Company
$1.13T
JNJJohnson & Johnson
$621.22B
ABBVAbbVie Inc.
$503.27B
UNHUnitedHealth Group Incorporated
$374.30B
MRKMerck & Co., Inc.
$369.78B